article thumbnail

DEA Proposes Dramatic Increase In Marijuana And Psychedelic Production In 2022, Calling For 6,300 Percent More MDMA Alone

Cannabis Law Report

The Drug Enforcement Administration (DEA) is proposing a dramatic increase in the legal production of marijuana and psychedelics like psilocybin, LSD, MDMA and DMT to be used in research next year. It wants to double the amount of marijuana extracts, psilocybin and psilocyn, quadruple mescaline and quintuple DMT.

DEA 96
article thumbnail

DEA Approves Cocaine Derivative for Parkinson’s Research. Why Not Cannabis?

Veriheal

But recent news of the DEA’s approval of a cocaine derivative for Parkinson’s disease research has left us scratching our heads. After receiving a petition three years prior, the DEA finally answered with action, making plans to deschedule [18F]FP-CIT , a controlled substance derived from cocaine.

DEA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

DEA Seeks to Increase Quota of Cannabis and Psilocybin for Research Purposes

SpeedWeed

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. View original article.

DEA 52
article thumbnail

The Epidiolex Effect: Will Other CBD Drugs Receive FDA and DEA Approval?

Freedom Leaf

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. billion by 2022. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA.

DEA 51
article thumbnail

CBD and Hemp Legal and Regulatory Roundup – May 13, 2022

Cannabis Law Report

Bravo Botanicals offers a line of organically-certified CBD products made with CBD extracted from their harvest, including cold-pressed drops and creams. Researchers want to force DEA to complete import application evaluation. Welcome to our weekly roundup of CBD and hemp-related legal and regulatory news: CBD. The Detroit News.

Hemp 52
article thumbnail

U.S. Cannabis Legalization Update: Who’s Still Waiting and Who May Legalize

Veriheal

However, the state’s legislative landscape is evolving, with the passage of a bill to fully legalize medical cannabis in 2022. In the meantime, the state allows CBD extracts for treating qualifying health conditions with less than 0.9% The only stipulation is that the extract has less than 0.9%

article thumbnail

Can I Import Marijuana Seeds to the U.S.?

Canna Law Blog

The seeds themselves have little to no THC, regardless of whether they were extracted from or may germinate into a plant that has more than 0.3% On January 6, 2022, DEA issued a letter that responded to a specific query on the treatment of cannabis seeds. trade law and the “reasonable care” standard U.S. federal law.

DEA 63